Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
August 2019, Vol 12, Special Issue: Payers' Perspectives In Oncology: ASCO 2019 Highlights
View Additional ASCO 2019 Coverage
FDA Approvals
Keytruda First PD-1 Inhibitor Approved as First-Line Monotherapy for Patients with Metastatic or Unresectable Head and Neck Cancer
Read More
FDA Approvals
Revlimid Approved for Patients with Follicular Lymphoma or Marginal-Zone Lymphoma
Read More
FDA Approvals
Xpovio Receives FDA Approval for Patients with Relapsed or Refractory Multiple Myeloma
Read More
FDA Approvals
Polivy FDA Approved for Patients with Relapsed or Refractory DLBCL
Read More
Prostate Cancer
Enzalutamide or Apalutamide Added to ADT Improves Outcomes in Hormone-Sensitive Prostate Cancer
Phoebe Starr
Read More
Disparities in Oncology
Access to Health Insurance Reduces Disparities in Cancer Care: The Case for the ACA
Phoebe Starr
Read More
Renal-Cell Carcinoma
Avelumab plus Axitinib New First-Line Standard of Care in Advanced Renal-Cell Carcinoma
Chase Doyle
Read More
Immunotherapy
Overcoming Current Barriers to Using CAR T-Cell Therapy in the Community Setting
Chase Doyle
Read More
Neuroendocrine Tumors
Combination Immune Blockade Promising in High-Grade Neuroendocrine Tumors: The DART “Basket” Clinical Trial
Phoebe Starr
Read More
Lung Cancer
BLU-667, Selective RET Inhibitor, Demonstrates Antitumor Activity in NSCLC with RET Fusion
Wayne Kuznar
Read More
1
2
3
Page 3 of 3
Results 21 - 30 of 30